BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld Asia
Home
» Summit Sells Dextra Lab Unit, Now Has Funds to Stay Afloat
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Summit Sells Dextra Lab Unit, Now Has Funds to Stay Afloat
Sep. 9, 2009
By
Nuala Moran
No Comments
LONDON - Summit Corp. plc completed the life-saving divestment of its services businesses, selling its Dextra Laboratories subsidiary to New Zealand Pharmaceuticals for £950,000 (US$1.6 million). (BioWorld International)
BioWorld Asia